Las Vegas, NV -- (SBWIRE) -- 01/04/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: XOMA Corp(NASDAQ:XOMA), AuRico Gold Inc(NYSE:AUQ), Merrimack Pharmaceuticals Inc(NASDAQ:MACK), Geron Corporation(NASDAQ:GERN)
XOMA Corp(NASDAQ:XOMA) the average volume of the stock remained 2.36 million shares. The stock opened the session at $6.66 and finished at the end of the day at $6.92 and the stock escalated 2.82%.The market capitalization of the stock remained 717.09 million. XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor.
For How Long XOMA will fight for Profitability? Read This Trend Analysis report
In the preceding trading session, AuRico Gold Inc(NYSE:AUQ) exchanged 2.85 million shares and the average volume remained 2.07 million shares. The stock closed the session at $3.83 with the gain of 4.64%. AuRico Gold Inc. operates as a gold producer with mines and projects in North America. The company?s core operations include the Young-Davidson gold mine in Northern Ontario, Canada; and the El Chanate mine in Sonora State, Mexico. AuRico Gold Inc. was founded in 1986 and is headquartered in Toronto, Canada.
Will AUQ Continue To Move Higher? Find Out Here
Merrimack Pharmaceuticals Inc(NASDAQ:MACK) enhanced 4.86% and its closing price was $5.59. The volume of the stock was 2.84 million shares and the average volume remained 2.39 million shares. The market capitalization of the stock remained 572.12 million. Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer in the United States. The company uses its Network Biology proprietary systems biology-based approach to biomedical research.
Why Should Investors Buy MACK After The Recent Gain? Just Go Here and Find Out
Geron Corporation(NASDAQ:GERN) exchanged 2.73 million shares in the previous trading session, and its average trading remained 5.72 million shares. GERN advanced 3.38% and it closed the trading at $4.90. The market capitalization of the stock remained 631.94 million. Geron Corporation is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
For How Long GERN’s Gloss will Attract Investors? Find out via this report
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)